Sennosides Tablets
» Sennosides Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of Sennosides.
Packaging and storage— Preserve in well-closed containers.
Identification— A portion of finely powdered Tablets, equivalent to about 20 mg of sennosides, responds to the Identification test under Sennosides.
Dissolution 711
Medium: water; 900 mL.
Apparatus 1: 100 rpm.
Time: 120 minutes.
Procedure— Determine the amount of sennosides dissolved, employing the procedure set forth in the Assay, making any necessary volumetric adjustments.
Tolerances— Not less than 75% (Q) of the labeled amount of sennosides is dissolved in 120 minutes.
Uniformity of dosage units 905: meet the requirements.
pH 7.0 phosphate buffer, Borate solution, Sodium dithionite solution, and Standard preparation Prepare as directed in the Assay under Sennosides.
Assay preparation— Weigh and finely powder not less than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 25 mg of sennosides, to a 25-mL volumetric flask. Add 20 mL of pH 7.0 phosphate buffer, sonicate to dissolve the sennosides, add pH 7.0 phosphate buffer to volume, and mix. Centrifuge the resulting suspension for 15 minutes at 3500 rpm. The supernatant is the Assay preparation.
Procedure— Proceed as directed for Procedure in the Assay under Sennosides. Calculate the quantity, in mg, of sennosides in the portion of Tablets taken by the formula:
25C(IU / IS)
in which C is the concentration, in mg per mL, of USP Sennosides RS, corrected for loss on drying, in the Standard preparation, and IU and IS are the fluorescence values observed for the solutions from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Maged H. Sharaf, Ph.D.
Senior Scientist
(DSB05) Dietary Supplements - Botanicals
Reference Standards Lili Wang, Technical Services Scientist
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
(BPC05) Biopharmaceutics05
USP32–NF27 Page 3551